Envestnet Asset Management Inc. Lowers Stock Holdings in Cencora, Inc. $COR

Envestnet Asset Management Inc. cut its stake in shares of Cencora, Inc. (NYSE:COR) by 3.5% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 525,162 shares of the company’s stock after selling 18,941 shares during the period. Envestnet Asset Management Inc. owned approximately 0.27% of Cencora worth $164,129,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Sax Wealth Advisors LLC acquired a new stake in shares of Cencora in the 2nd quarter worth $222,000. Valmark Advisers Inc. raised its holdings in Cencora by 4.6% during the second quarter. Valmark Advisers Inc. now owns 1,109 shares of the company’s stock worth $333,000 after purchasing an additional 49 shares in the last quarter. Maryland State Retirement & Pension System lifted its position in Cencora by 9.7% in the second quarter. Maryland State Retirement & Pension System now owns 8,899 shares of the company’s stock valued at $2,668,000 after purchasing an additional 788 shares during the period. Blair William & Co. IL boosted its holdings in Cencora by 1.7% in the 2nd quarter. Blair William & Co. IL now owns 21,121 shares of the company’s stock valued at $6,333,000 after purchasing an additional 353 shares in the last quarter. Finally, Callan Family Office LLC raised its stake in shares of Cencora by 65.9% during the 2nd quarter. Callan Family Office LLC now owns 49,069 shares of the company’s stock worth $14,713,000 after buying an additional 19,487 shares in the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora News Summary

Here are the key news stories impacting Cencora this week:

• Positive Sentiment: Q1 2026 earnings call highlighted strong U.S. growth that offset international headwinds; management commentary helped support the upbeat tone after results. Cencora Inc (COR) Q1 2026 Earnings Call Highlights
• Positive Sentiment: Cencora closed its deal with OneOncology; coverage of the terms characterizes the agreement as reflecting trust between parties, which supports the company’s oncology services strategy and potential revenue synergies. As Cencora Closes With OneOncology
• Neutral Sentiment: Evercore ISI set a new $420 price target (down from $440) but kept an “outperform” rating — the target implies meaningful upside from current levels despite the trim. Cencora Given New $420.00 Price Target at Evercore ISI
• Neutral Sentiment: Market write-ups and stock-flow coverage are highlighting the mix of EPS beats and revenue dynamics as reasons for the intraday move, keeping attention on upcoming guidance and international performance. Cencora stock trades up, here is why
• Negative Sentiment: Cencora missed Q4 CY2025 revenue estimates, which tempers enthusiasm from the EPS beat and raises questions about near-term revenue momentum. Cencora misses Q4 revenue estimates
• Negative Sentiment: Recent intraday coverage noted the stock underperformed peers on Wednesday, suggesting investors are watching competitive execution and margin trends across the sector. Cencora underperforms competitors

Insider Activity at Cencora

In related news, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The shares were sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the transaction, the chief executive officer owned 65,746 shares of the company’s stock, valued at approximately $24,105,113.44. This represents a 7.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $345.00, for a total transaction of $578,565.00. Following the sale, the executive vice president owned 18,796 shares in the company, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 20,316 shares of company stock valued at $7,151,265. 0.38% of the stock is owned by insiders.

Analyst Ratings Changes

COR has been the topic of a number of recent analyst reports. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a report on Friday, November 28th. Robert W. Baird set a $415.00 price target on shares of Cencora in a research note on Tuesday, January 13th. TD Cowen raised their price objective on shares of Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Weiss Ratings upgraded shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research report on Thursday. Finally, Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $394.75.

Cencora Stock Performance

Shares of COR opened at $359.15 on Friday. Cencora, Inc. has a 12-month low of $237.71 and a 12-month high of $377.54. The stock has a market cap of $69.67 billion, a P/E ratio of 43.17, a PEG ratio of 1.63 and a beta of 0.68. The company has a current ratio of 0.92, a quick ratio of 0.55 and a debt-to-equity ratio of 3.62. The company has a 50-day moving average of $345.91 and a two-hundred day moving average of $325.92.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, topping analysts’ consensus estimates of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business had revenue of $85.93 billion during the quarter, compared to analysts’ expectations of $86.12 billion. During the same period last year, the company posted $3.73 EPS. The company’s revenue was up 5.5% on a year-over-year basis. As a group, research analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Investors of record on Friday, February 13th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, February 13th. Cencora’s dividend payout ratio (DPR) is currently 30.19%.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.